NEW YORK (GenomeWeb) – Protagen said today it has entered a collaboration with the Gustave Roussy Institute of Oncology to identify biomarkers for immune system-related side effects in cancer patients treated with checkpoint inhibitors.

Under the collaboration, the parties will use Protagen's SeroTag platform, which simultaneously measures autoantibody levels for thousands of antigens, to test cancer immunotherapy patients for markers linked to immune-related adverse events (irAEs) and, ultimately, develop a risk-profiling test for patients undergoing immunotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.